Next Article in Journal
MTOR Signaling and Metabolism in Early T Cell Development
Next Article in Special Issue
Surgical Management of Hereditary Breast Cancer
Previous Article in Journal
Craniofacial Diseases Caused by Defects in Intracellular Trafficking
Previous Article in Special Issue
New Insights into the Therapeutic Applications of CRISPR/Cas9 Genome Editing in Breast Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice

1
Division of Medical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari ‘Aldo Moro’, A.O.U. Consorziale Policlinico di Bari, 70121 Bari, Italy
2
National Cancer Research Center, Tumori Institute IRCCS Giovanni Paolo II, 70121 Bari, Italy
3
Interdisciplinary Department of Medicine, Section of Sciences and Technologies of Laboratory Medicine, University of Bari, 70121 Bari, Italy
*
Author to whom correspondence should be addressed.
Genes 2021, 12(5), 727; https://doi.org/10.3390/genes12050727
Submission received: 19 April 2021 / Revised: 9 May 2021 / Accepted: 10 May 2021 / Published: 13 May 2021
(This article belongs to the Special Issue Breast Cancer Genetics: Diagnostic and Treatment)

Abstract

Molecular alterations of the Ataxia-telangiectasia (AT) gene are frequently detected in breast cancer (BC), with an incidence ranging up to 40%. The mutated form, the Ataxia-telangiectasia mutated (ATM) gene, is involved in cell cycle control, apoptosis, oxidative stress, and telomere maintenance, and its role as a risk factor for cancer development is well established. Recent studies have confirmed that some variants of ATM are associated with an increased risk of BC development and a worse prognosis. Thus, many patients harboring ATM mutations develop intermediate- and high-grade disease, and there is a higher rate of lymph node metastatic involvement. The evidence concerning a correlation of ATM gene mutations and the efficacy of therapeutic strategies in BC management are controversial. In fact, ATM mutations may sensitize cancer cells to platinum-derived drugs, as BRCA1/2 mutations do, whereas their implications in objective responses to hormonal therapy or target-based agents are not well defined. Herein, we conducted a review of the role of ATM gene mutations in BC development, prognosis, and different treatment strategies.
Keywords: ATM gene; breast cancer; risk; outcome; treatment ATM gene; breast cancer; risk; outcome; treatment
Graphical Abstract

Share and Cite

MDPI and ACS Style

Stucci, L.S.; Internò, V.; Tucci, M.; Perrone, M.; Mannavola, F.; Palmirotta, R.; Porta, C. The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. Genes 2021, 12, 727. https://doi.org/10.3390/genes12050727

AMA Style

Stucci LS, Internò V, Tucci M, Perrone M, Mannavola F, Palmirotta R, Porta C. The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. Genes. 2021; 12(5):727. https://doi.org/10.3390/genes12050727

Chicago/Turabian Style

Stucci, Luigia Stefania, Valeria Internò, Marco Tucci, Martina Perrone, Francesco Mannavola, Raffaele Palmirotta, and Camillo Porta. 2021. "The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice" Genes 12, no. 5: 727. https://doi.org/10.3390/genes12050727

APA Style

Stucci, L. S., Internò, V., Tucci, M., Perrone, M., Mannavola, F., Palmirotta, R., & Porta, C. (2021). The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. Genes, 12(5), 727. https://doi.org/10.3390/genes12050727

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop